Stockholm, Sweden – June 1, 2024 – Stratipath, a forerunner in AI-based cancer diagnostics, is pleased to announce that its innovative solution, Stratipath Breast, is now officially registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This registration allows healthcare providers across the United Kingdom access to the AI-based prognostic tool for breast cancer risk profiling.

Stratipath Breast has been CE-IVD marked for some time, enabling its clinical use within the European Union. Over the past year and a half, the tool has already been in clinical use at several hospitals supporting healthcare professionals with faster and more accurate decision-making for breast cancer treatment. With the UK registration, healthcare providers can now use Stratipath Breast to offer rapid, AI-driven analysis of routine histopathology slides, delivering results within the hour.

“We are excited to make Stratipath Breast available to clinicians across the UK,” said Annica Jämtén Ericsson, COO of Stratipath. “This registration is a crucial step in broadening access to AI-based precision diagnostics, which will enhance cancer care by improving the speed and accuracy of risk stratification.”

Stratipath Breast provides clinicians with additional prognostic information at the point of diagnosis. By offering fast and affordable analysis it serves as a cost-effective alternative to gene expression tests and helps broaden access to precision diagnostics for more patients.

This innovation empowers healthcare providers to deliver high-quality care, reducing laboratory time and healthcare costs, which is vital for improving patient outcomes and ensuring more equitable cancer diagnostics.